| Name | Title | Contact Details |
|---|
Reflexion Health is a digital healthcare company dedicated to transforming traditional medicine and improving clinical outcomes by using innovative technology solutions to deliver patient-centered care at reduced costs. VERA™, Reflexion Health’s signature solution, is an FDA-cleared Virtual Exercise Rehabilitation Assistant that detects motion and remotely monitors the effectiveness of prescribed physical therapy in real-time. VERA brings the guidance of a physical therapist into the home to coach and motivate patients through recovery from joint replacement surgery or as a preventative therapy to reduce falls.
St Jude Medical is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VentureMed Group, Inc. is a commercial-stage medical device company that develops and markets cost-effective interventional devices to improve the treatment of peripheral artery disease.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.
With more than a 60-year history of pioneering products to treat millions of patients, Cordis is a worldwide leader in the development and manufacturing of interventional cardiovascular technology. Cordis established a legacy of high-quality and minimally-invasive cardiovascular products; and has built a robust global footprint with operations in more than 60 countries around the world. As from August 2, 2021, Cordis is a standalone company, and is committed to investing $300 million to accelerate innovation in its broad product portfolio. Building on our storied brand, we are unleashing our potential to be a $10 billion leader bringing new technology to the market through bold action at speed.